4 citations
,
October 2024 in “Cureus” PCOS may increase the risk of high blood pressure and heart issues.
2 citations
,
February 2018 in “InTech eBooks” PCOS is complex, affects many, and requires informed management and lifestyle changes.
1 citations
,
February 2025 in “Notulae Scientia Biologicae” Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
October 2025 in “Cermin Dunia Kedokteran” Chronic obstructive pulmonary disease (COPD) is managed with personalized medication to ease symptoms and improve life quality.
September 2025 in “International Journal of Innovative Technologies in Social Science” Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
August 2025 in “PLoS ONE” Improving access to hidradenitis suppurativa care can reduce social disparities.
June 2025 in “Saratov Medical Journal” Ongoing research and innovation are crucial for improving skin care and treatment.
September 2022 in “Skin appendage disorders” Seborrheic dermatitis may contribute to the development of central centrifugal cicatricial alopecia.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
19 citations
,
April 2014 in “Veterinary Dermatology” Demodicosis should be considered in cats with facial skin issues exposed to inhalant glucocorticoids.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
9 citations
,
September 2019 in “Clinical Cosmetic and Investigational Dermatology” Cal/BD aerosol foam effectively treats scalp psoriasis, improving symptoms and patient satisfaction.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
9 citations
,
July 2018 in “European Journal of Dermatology” Brodalumab effectively treated a man's severe hand and foot psoriasis.
39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” Methotrexate plus prednisolone had the fewest serious side effects.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.